## Plenary Speakers

**PL09 - Paul Ehrlich Award Lecture - Chemical Biology on the Genome**

Prof. Sir Shankar BALASUBRAMANIAN  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

**PL17 - Nanoparticle-based Strategies in Oncology**

Prof. Jean-Pierre BENOIT  
(UNIVERSITY OF ANGERS, Angers, France)

**PL22 - Two Adventures in Chemical Biology - in vivo Chemistry and Real-time Optical Medical Imaging**

Prof. Mark BRADLEY  
(UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom)

**PL01 - Disrupting Cancer Care & Outcomes by Putting Patients in the Driving Seat**

Dr Anne BRUINVELS  
(PX HEALTHCARE, London, United Kingdom)

**PL21 - Pierre Fabre Award Lecture**  
PROTAC-mediated Protein Degradation: A New Therapeutic Modality

Prof. Craig CREWS  
(UNIVERSITY OF YALE, New Haven, United States)

**PL04 - Ghrelin Receptor Ligands: from the Bench to the Drug on the Market**

Dr Jean-Alain FEHRENTZ  
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)

**PL11 - Identification of Chemokine Neutraligands Targeting Atopic Diseases and Hyperalgesia**

Dr Jean-Luc GALZI  
(CNRS-UNIVERSITY OF STRASBOURG, Illkirch, France)

**PL10 - Ancient and Modern Scaffolds for Biologically Active Chemical Space**

Prof. Arasu GANESAN  
(UNIVERSITY OF EAST ANGLIA, Norwich, United Kingdom)

**PL06 - Structure-guided Development of Selective GPCR Ligands**
Confirmed Speakers

Prof. Peter GMEINER  
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

PL07 - Late Stage Fluorination for Medicine
Prof. Véronique GOUVERNEUR  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

PL15 - Identifying Inter-Helical Interactions Involved in GPCR Structure-Function and the Forces that Determine Receptor-Ligand Residence Time
Dr. Alexander HEIFETZ  
(EVOTEC, Abingdon, United Kingdom)

PL05 - Structure-Based Drug Discovery for G Protein-Coupled Purine Receptors
Prof. Kenneth A. JACOBSON  
(NIDDK, Bethesda, United States)

PL19 - Chemical Tools to Probe Reversible Lysine Acetylation
Prof. Manfred JUNG  
(ALBERT LUDWIGS UNIVERSITY OF FREIBURG, Freiburg, Germany)

PL14 - Pharmacophore-based Analysis of Molecular Dynamics Trajectories: Towards Understanding KD of Protein Ligands
Prof. Thierry LANGER  
(UNIVERSITY OF VIENNA, Vienna, Austria)

PL13 - Potential Therapeutic Targets in the Brain Renin-Agiotensin and Apelinergic Systems for Treatment of Cardiovascular Diseases
Dr. Catherine LLORENS-CORTES  
(INSERM/COLLÈGE DE FRANCE, Paris, France)

PL18 - Chemistry as the Helping Tool to Develop New Therapeutic Strategies
Prof. Maria Luz LOPEZ RODRIGUEZ  
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

PL20 - The Confobody Technology, a New Platform to Enable Fragment Screening on GPCRs
Dr. Christel MENET  
(CONFO THERAPEUTICS, Brussels, Belgium)
Confirmed Speakers

PL02 - Chemogenetic Approaches to Validate Poorly Characterised GPCRS
   Prof. Graeme MILLIGAN
   (UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

PL08 - Single Electron Processes Enabling Organic Synthesis
   Prof. Gary A. MOLANDER
   (UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

PL12 - Discovery of Foliglurax, an mGluR4 PAM for the Treatment of Parkinson’s Disease
   Dr Stephan SCHANN
   (DOMAIN THERAPEUTICS SA, Illkirch, France)

PL03 - Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism
   Dr Patrick SCHNIDER
   (ROCHE PHARMACEUTICAL, Zürich, Switzerland)

PL23 - Therapeutic In Vivo Synthetic Chemistry
   Prof. Nori TANAKA
   (RIKEN, Saitama, Japan)

PL16 - Cellular Delivery and Oral Uptake of Cyclic Peptides
   Dr Thomas VORHERR
   (NOVARTIS, Basel, Switzerland)

Keynote Speakers

KL05 - Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering
   Dr Julie CHARTON
   (UNIVERSITY OF LILLE, INSTITUT PASTEUR DE LILLE, Lille, France)

KL06 - Drug-target Residence Time – a Misleading Concept
   Dr Rutger FOLMER
   (MERCACHEM, Nijmegen, The Netherlands)

KL04 - Inducible Chemical-genetic Fluorescent Markers for Bioimaging
Confirmed Speakers

**KL02 - Discovery of New Brain Penetrating Neuropeptide S Receptor (NPSR) Antagonists**

Dr Arnaud GAUTIER  
(ECOLE NORMALE SUPÉRIEURE, Paris, France)

**KL01 - Discovery of The Clinical Candidate Ribuvaptan, a Dual Acting Vasopressin V1a/V2 Receptor Antagonist for the Treatment of Heart Failure**

Dr Julien POTHIER  
(IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland)


Dr Carsten SCHMECK  
(BAYER, Wuppertal, Germany)

Dr Isabelle TEXIER  
(LETI-HEALTH, Grenoble, France)